<p>Intellia Therapeutics, Inc.（纳斯达克代码：NTLA - 获取免费报告）目前被 24 家评级公司给予了 “持有” 的共识推荐，Marketbeat Ratings 报告称。三位股票研究分析师对该股票给予了卖出推荐，十位给予了持有推荐，十一位则给予了买入推荐。在过去一年中，覆盖该股票的经纪商的平均 12 个月目标价为 18.4348 美元。</p>
<p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
<ul>
<li>高盛在其看涨的标准普尔 500 展望中重点关注这 3 只股票</li>
</ul>
<p>几家经纪公司最近对 NTLA 发布了报告。巴克莱将 Intellia Therapeutics 的目标价从 24.00 美元下调至 14.00 美元，并在 11 月 7 日的研究报告中对该股票设定了 “增持” 评级。桑福德·C·伯恩斯坦在 10 月 28 日的报告中对 Intellia Therapeutics 设定了 14.50 美元的目标价。韦斯评级在 10 月 8 日的研究报告中重申了对 Intellia Therapeutics 的 “卖出（d-）” 评级。富国银行将 Intellia Therapeutics 的目标价从 17.00 美元下调至 12.00 美元，并在 11 月 7 日的报告中对该公司设定了 “等权重” 评级。最后，查尔丹资本在 11 月 7 日的研究报告中将 Intellia Therapeutics 的目标价从 48.00 美元下调至 26.00 美元，并对该股票设定了 “买入” 评级。</p>
<p><strong>阅读我们对 NTLA 的最新分析</strong></p>
<h2>Intellia Therapeutics 股价上涨 3.9%</h2>
<ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
<p>NTLA 的股票在周五以 9.23 美元开盘。该公司的市值为 10.7 亿美元，市盈率为-2.16，贝塔值为 2.13。Intellia Therapeutics 的 12 个月低点为 5.90 美元，12 个月高点为 28.25 美元。该股票的 50 日移动平均线为 12.99 美元，200 日移动平均线为 12.61 美元。</p>
<p>Intellia Therapeutics（纳斯达克代码：NTLA - 获取免费报告）最后一次公布财报是在 11 月 6 日，报告显示该公司本季度每股收益（EPS）为（0.92 美元），超出分析师的共识预期（1.02 美元）0.10 美元。该公司本季度的收入为 1378 万美元，而分析师预期为 1412 万美元。Intellia Therapeutics 的股本回报率为-57.01%，净利润率为-774.94%。该公司的收入同比增长了 51.6%。去年同期，该公司每股收益为（1.34 美元）。股票研究分析师预测 Intellia Therapeutics 在本年度将发布-5.07 美元的每股收益。</p>
<h2>内部人士下注</h2>
<ul>
<li>2 只基因编辑股票有望在 2025 年强势回归</li>
</ul>
<p>在其他 Intellia Therapeutics 的新闻中，首席会计官 Michael P. Dube 在 10 月 1 日的交易中出售了 1871 股 Intellia Therapeutics 的股票。股票以平均价格 17.38 美元出售，总交易额为 32,517.98 美元。出售后，首席会计官持有公司股票 55,266 股，价值 960,523.08 美元。此次交易使其持股减少了 3.27%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。内部人士持有公司股票的 3.10%。</p>
<h2>Intellia Therapeutics 的机构交易</h2>
<p>几家大型投资者最近买入和卖出了 NTLA 的股票。Contrarius Group Holdings Ltd 在第三季度将其在 Intellia Therapeutics 的持股增加了 279.4%。Contrarius Group Holdings Ltd 现在拥有 5889936 股公司股票，价值 101,719,000 美元，在上个季度又购买了 4337428 股。Jupiter Asset Management Ltd.在第三季度获得了 Intellia Therapeutics 的新头寸，价值 23,519,000 美元。Marex Group plc 在第二季度获得了 Intellia Therapeutics 的新头寸，价值 5,849,000 美元。Farallon Capital Management LLC 在第三季度购买了 Intellia Therapeutics 的新股份，价值 10,486,000 美元。最后，先锋集团在第一季度将其在 Intellia Therapeutics 的持股增加了 5.5%。先锋集团现在拥有 10752031 股公司股票，价值 76,447,000 美元，在上个季度又收购了 561978 股。对冲基金和其他机构投资者持有公司股票的 88.77%。</p>
<h2>Intellia Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Intellia Therapeutics, Inc. 纳斯达克：NTLA 是一家临床阶段的生物技术公司，专注于开发使用 CRISPR/Cas9 平台的潜在治愈性基因编辑疗法。该公司的研究涵盖 CRISPR/Cas9 的体内和体外应用，旨在通过一次给药纠正或禁用致病基因。Intellia 的主要体内项目针对转甲状腺素淀粉样变（ATTR），通过将 CRISPR/Cas9 机制直接输送到肝脏，而其他前临床工作则追求对血友病 A、遗传性血管水肿和其他遗传疾病的治疗。</p>
<p>除了其体内管线，Intellia 还与战略合作伙伴合作，以扩大其基因编辑方法的影响。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Intellia Therapeutics 更好</li>
<li>在哪里可以找到财报电话会议记录</li>
<li>这 3 家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>经济报告在成功投资策略中的作用</li>
<li>3 只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>投资者需要了解的击败市场的信息</li>
<li>该 ETF 在美联储降息后获得了重大顺风</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Intellia Therapeutics 吗？</h2>
<p>在考虑 Intellia Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐现在购买，以便在更广泛的市场注意到之前……而 Intellia Therapeutics 并不在名单上。</p>
<p>虽然 Intellia Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Intellia治疗

<p>Intellia Therapeutics, Inc.（纳斯达克代码：NTLA）获得了 24 家评级公司的共识 “持有” 推荐。分析师的意见各不相同，其中 3 家推荐卖出，10 家持有，11 家买入。12 个月的平均目标价格为 18.43 美元。最近的报告显示，巴克莱、富国银行和查丹资本下调了目标价格。该股票开盘价为 9.23 美元，市值为 10.7 亿美元。Intellia 的收入同比增长了 51.6%，内部人士持有该股票的 3.10%</p>

<p>Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus recommendation of &#34;Hold&#34; by the twenty-four ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $18.4348.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.（纳斯达克代码：NTLA - 获取免费报告）目前被 24 家评级公司给予了 “持有” 的共识推荐，Marketbeat Ratings 报告称。三位股票研究分析师对该股票给予了卖出推荐，十位给予了持有推荐，十一位则给予了买入推荐。在过去一年中，覆盖该股票的经纪商的平均 12 个月目标价为 18.4348 美元。</p>
</div><p>Get <strong>Intellia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>高盛在其看涨的标准普尔 500 展望中重点关注这 3 只股票</li>
</ul>
</div><p>Several brokerages have recently issued reports on NTLA. Barclays dropped their target price on shares of Intellia Therapeutics from $24.00 to $14.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, November 7th. Sanford C. Bernstein set a $14.50 price objective on Intellia Therapeutics in a report on Tuesday, October 28th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. Wells Fargo &amp; Company reduced their target price on Intellia Therapeutics from $17.00 to $12.00 and set an &#34;equal weight&#34; rating for the company in a report on Friday, November 7th. Finally, Chardan Capital lowered their price target on Intellia Therapeutics from $48.00 to $26.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th.</p>
<div class="lb-trans"><p>几家经纪公司最近对 NTLA 发布了报告。巴克莱将 Intellia Therapeutics 的目标价从 24.00 美元下调至 14.00 美元，并在 11 月 7 日的研究报告中对该股票设定了 “增持” 评级。桑福德·C·伯恩斯坦在 10 月 28 日的报告中对 Intellia Therapeutics 设定了 14.50 美元的目标价。韦斯评级在 10 月 8 日的研究报告中重申了对 Intellia Therapeutics 的 “卖出（d-）” 评级。富国银行将 Intellia Therapeutics 的目标价从 17.00 美元下调至 12.00 美元，并在 11 月 7 日的报告中对该公司设定了 “等权重” 评级。最后，查尔丹资本在 11 月 7 日的研究报告中将 Intellia Therapeutics 的目标价从 48.00 美元下调至 26.00 美元，并对该股票设定了 “买入” 评级。</p>
</div><p><strong>Read Our Latest Analysis on NTLA</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 NTLA 的最新分析</strong></p>
</div><h2>Intellia Therapeutics Trading Up 3.9%</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 股价上涨 3.9%</h2>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能翻倍</li>
</ul>
</div><p>Shares of NTLA opened at $9.23 on Friday. The firm has a market cap of $1.07 billion, a P/E ratio of -2.16 and a beta of 2.13. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The stock's 50 day moving average is $12.99 and its two-hundred day moving average is $12.61.</p>
<div class="lb-trans"><p>NTLA 的股票在周五以 9.23 美元开盘。该公司的市值为 10.7 亿美元，市盈率为-2.16，贝塔值为 2.13。Intellia Therapeutics 的 12 个月低点为 5.90 美元，12 个月高点为 28.25 美元。该股票的 50 日移动平均线为 12.99 美元，200 日移动平均线为 12.61 美元。</p>
</div><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business's revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.34) EPS. Equities research analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.</p>
<div class="lb-trans"><p>Intellia Therapeutics（纳斯达克代码：NTLA - 获取免费报告）最后一次公布财报是在 11 月 6 日，报告显示该公司本季度每股收益（EPS）为（0.92 美元），超出分析师的共识预期（1.02 美元）0.10 美元。该公司本季度的收入为 1378 万美元，而分析师预期为 1412 万美元。Intellia Therapeutics 的股本回报率为-57.01%，净利润率为-774.94%。该公司的收入同比增长了 51.6%。去年同期，该公司每股收益为（1.34 美元）。股票研究分析师预测 Intellia Therapeutics 在本年度将发布-5.07 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票有望在 2025 年强势回归</li>
</ul>
</div><p>In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer owned 55,266 shares of the company's stock, valued at $960,523.08. The trade was a 3.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Intellia Therapeutics 的新闻中，首席会计官 Michael P. Dube 在 10 月 1 日的交易中出售了 1871 股 Intellia Therapeutics 的股票。股票以平均价格 17.38 美元出售，总交易额为 32,517.98 美元。出售后，首席会计官持有公司股票 55,266 股，价值 960,523.08 美元。此次交易使其持股减少了 3.27%。该出售在向 SEC 提交的文件中披露，文件可通过此链接获取。内部人士持有公司股票的 3.10%。</p>
</div><h2>Institutional Trading of Intellia Therapeutics</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 的机构交易</h2>
</div><p>Several large investors have recently bought and sold shares of NTLA. Contrarius Group Holdings Ltd grew its position in shares of Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company's stock valued at $101,719,000 after purchasing an additional 4,337,428 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new position in Intellia Therapeutics during the third quarter worth $23,519,000. Marex Group plc acquired a new position in Intellia Therapeutics during the second quarter worth $5,849,000. Farallon Capital Management LLC purchased a new stake in Intellia Therapeutics in the 3rd quarter valued at $10,486,000. Finally, Vanguard Group Inc. increased its stake in shares of Intellia Therapeutics by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after acquiring an additional 561,978 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了 NTLA 的股票。Contrarius Group Holdings Ltd 在第三季度将其在 Intellia Therapeutics 的持股增加了 279.4%。Contrarius Group Holdings Ltd 现在拥有 5889936 股公司股票，价值 101,719,000 美元，在上个季度又购买了 4337428 股。Jupiter Asset Management Ltd.在第三季度获得了 Intellia Therapeutics 的新头寸，价值 23,519,000 美元。Marex Group plc 在第二季度获得了 Intellia Therapeutics 的新头寸，价值 5,849,000 美元。Farallon Capital Management LLC 在第三季度购买了 Intellia Therapeutics 的新股份，价值 10,486,000 美元。最后，先锋集团在第一季度将其在 Intellia Therapeutics 的持股增加了 5.5%。先锋集团现在拥有 10752031 股公司股票，价值 76,447,000 美元，在上个季度又收购了 561978 股。对冲基金和其他机构投资者持有公司股票的 88.77%。</p>
</div><h2>Intellia Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Intellia Therapeutics, Inc NASDAQ: NTLA is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc. 纳斯达克：NTLA 是一家临床阶段的生物技术公司，专注于开发使用 CRISPR/Cas9 平台的潜在治愈性基因编辑疗法。该公司的研究涵盖 CRISPR/Cas9 的体内和体外应用，旨在通过一次给药纠正或禁用致病基因。Intellia 的主要体内项目针对转甲状腺素淀粉样变（ATTR），通过将 CRISPR/Cas9 机制直接输送到肝脏，而其他前临床工作则追求对血友病 A、遗传性血管水肿和其他遗传疾病的治疗。</p>
</div><p>Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.</p>
<div class="lb-trans"><p>除了其体内管线，Intellia 还与战略合作伙伴合作，以扩大其基因编辑方法的影响。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Intellia Therapeutics</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li>
<li>The Role Economic Reports Play in a Successful Investment Strategy</li>
<li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Intellia Therapeutics 更好</li>
<li>在哪里可以找到财报电话会议记录</li>
<li>这 3 家银行在年末前上涨，但这种趋势会持续吗？</li>
<li>经济报告在成功投资策略中的作用</li>
<li>3 只飙升的股票刚刚获得标准普尔 500 的最终认可</li>
<li>投资者需要了解的击败市场的信息</li>
<li>该 ETF 在美联储降息后获得了重大顺风</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NTLA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Intellia Therapeutics 吗？</h2>
</div><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Intellia Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐现在购买，以便在更广泛的市场注意到之前……而 Intellia Therapeutics 并不在名单上。</p>
</div><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Intellia Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Intellia Therapeutics, Inc.（纳斯达克股票代码：NTLA）获得分析师一致推荐 “持有” 评级